Gute Besserung Hauser, LLC – Trademark Portfolio
Entity Type: 16
Gute Besserung Hauser, LLC holds 29 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 28 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 7 trademarks are registered and 2 are pending. Notable registered marks include ISODINE, TESACOF, GELMICIN, NEUROVIT, and BUSCAPINA. The owner is based in New York, NY.
1 Maiden Lane 5th Floor
New York, NY 10038
Showing of trademarks Trademarks
Trademark Classifications
Gute Besserung Hauser, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Gute Besserung Hauser, LLC have?
Gute Besserung Hauser, LLC has 29 U.S. trademarks filed with the USPTO. Of these, 7 registered, 2 pending, 20 abandoned.
What trademark classes does Gute Besserung Hauser, LLC file in?
Gute Besserung Hauser, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Gute Besserung Hauser, LLC's most well-known trademarks?
Gute Besserung Hauser, LLC's registered trademark portfolio includes well-known marks such as ISODINE, TESACOF, GELMICIN, NEUROVIT, and BUSCAPINA. These are among 7 currently registered trademarks in the portfolio.
What is Gute Besserung Hauser, LLC's trademark registration success rate?
Gute Besserung Hauser, LLC has a 26% trademark registration rate, with 7 out of 27 resolved applications resulting in successful registration. Currently, 2 applications are pending review.